These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31377765)

  • 1. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis.
    Mei H; Yang T; Wang J; Wang R; Cai Y
    J Antimicrob Chemother; 2019 Dec; 74(12):3423-3431. PubMed ID: 31377765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
    Ni W; Han Y; Zhao J; Wei C; Cui J; Wang R; Liu Y
    Int J Antimicrob Agents; 2016 Feb; 47(2):107-16. PubMed ID: 26742726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
    Kengkla K; Kongpakwattana K; Saokaew S; Apisarnthanarak A; Chaiyakunapruk N
    J Antimicrob Chemother; 2018 Jan; 73(1):22-32. PubMed ID: 29069421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline-Containing Regimens and Multi Drug-Resistant
    Sodeifian F; Zangiabadian M; Arabpour E; Kian N; Yazarlou F; Goudarzi M; Centis R; Seghatoleslami ZS; Kameh MC; Danaei B; Goudarzi H; Nasiri MJ; Sotgiu G; Migliori GB
    Microb Drug Resist; 2023 Aug; 29(8):344-359. PubMed ID: 37192494
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.
    Liu J; Shu Y; Zhu F; Feng B; Zhang Z; Liu L; Wang G
    J Glob Antimicrob Resist; 2021 Mar; 24():136-147. PubMed ID: 32889142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
    Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
    Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?
    Tasbakan MS; Pullukcu H; Sipahi OR; Tasbakan MI; Aydemir S; Bacakoglu F
    J Chemother; 2011 Dec; 23(6):345-9. PubMed ID: 22233818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis.
    Wang J; Niu H; Wang R; Cai Y
    Int J Antimicrob Agents; 2019 Apr; 53(4):383-400. PubMed ID: 30447379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
    Chuang YC; Cheng CY; Sheng WH; Sun HY; Wang JT; Chen YC; Chang SC
    BMC Infect Dis; 2014 Feb; 14():102. PubMed ID: 24564226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.
    Ye JJ; Lin HS; Kuo AJ; Leu HS; Chiang PC; Huang CT; Lee MH
    J Infect; 2011 Nov; 63(5):351-61. PubMed ID: 21846481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Ye JJ; Lin HS; Yeh CF; Wu YM; Huang PY; Yang CC; Huang CT; Lee MH
    BMC Infect Dis; 2016 Aug; 16():374. PubMed ID: 27496018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis.
    Zha L; Pan L; Guo J; French N; Villanueva EV; Tefsen B
    Adv Ther; 2020 Mar; 37(3):1049-1064. PubMed ID: 32006240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii.
    Zhou Y; Chen X; Xu P; Zhu Y; Wang K; Xiang D; Wang F; Banh HL
    BMC Pharmacol Toxicol; 2019 Apr; 20(1):19. PubMed ID: 31023357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.
    Shin JA; Chang YS; Kim HJ; Kim SK; Chang J; Ahn CM; Byun MK
    Yonsei Med J; 2012 Sep; 53(5):974-84. PubMed ID: 22869481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant
    Wang X; Hu Y; Que CL; Zhang H; Huang JJ; Cao J; Jin Z; Wang GF; Zhang W
    Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):2996-3000. PubMed ID: 29061006
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis.
    Gong J; Su D; Shang J; Yu H; Du G; Lin Y; Sun Z; Liu G
    Medicine (Baltimore); 2019 Sep; 98(38):e17091. PubMed ID: 31567945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
    Wang Q; Huang M; Zhou S
    J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.